<DOC>
	<DOCNO>NCT00715572</DOCNO>
	<brief_summary>The objective study analyze feature monotherapy L-T4 comparison combine therapy L-T4 L-T3 patient primary hypothyroidism .</brief_summary>
	<brief_title>Combined Therapy With L-Thyroxine L-Triiodothyronine Compared L-Thyroxine Alone</brief_title>
	<detailed_description>We conduct randomize control study crossover design 36 premenopausal woman overt primary hypothyroidism ( reduce T4 concentration accompany increased TSH concentration time initial diagnosis ) receive thyroid hormone . All patient divide two group : patient Group A ( n=20 ) randomize L-T4 dose 1,6 μg per kg , follow combined L-T4 L-T3 ; 16 woman Group B receive combination L-T4+L-T3 ( dose L-T4 reduce 25 μg replace 12,5 μg L-T3 ) , follow monotherapy L-T4 . The treatment period last 6 month . Patients examine baseline end treatment period.Blood sample obtain measure serum TSH , free T4 , free T3 , lipid profile , osteocalcin . Urine sample collect measure urinary deoxypyridinoline / creatinine ratio . 24-hour ECG-monitoring , osteodensitometry psychological testing also perform baseline end treatment period .</detailed_description>
	<mesh_term>Hypothyroidism</mesh_term>
	<criteria>Premenopausal woman overt primary hypothyroidism ( reduce T4 concentration accompany increased TSH concentration time initial diagnosis ) receive thyroid hormone Peri postmenopause Pregnancy Major comorbidity Use drug affect metabolism bioavailability thyroid hormone preparation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>hypothyroidism , treatment , thyroxine , triiodothyronine</keyword>
</DOC>